Stocktoria
IMMUCELL CORP /DE/ ICCC
Nasdaq · stock · In Vitro & In Vivo Diagnostic Substances · website · IPO 1987-05-01
IMMUCELL CORP /DE/ financials (annual)
Bars are annual figures from 2016 to 2025; red bars are negative (a loss or cash outflow).
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $27.6M | $26.5M | $17.5M | $18.6M | $19.2M | $15.3M | $13.7M | $11.0M | $10.4M | — |
| Gross profit | $11.4M | $7.9M | $3.9M | $7.6M | $8.7M | $6.9M | $6.7M | $5.2M | $5.2M | $5.4M |
| R&D expense | $3.0M | $3.9M | $4.4M | $4.5M | $4.2M | $4.4M | $3.7M | $3.5M | $2.0M | $1.2M |
| Operating income | $1.6M | -$1.6M | -$5.7M | -$2.3M | $257,385 | -$1.4M | -$953,908 | -$1.4M | -$242,845 | $890,204 |
| Interest expense | — | — | $475,598 | $348,536 | $314,359 | — | — | — | — | — |
| Income tax | $11,570 | $10,056 | $4,627 | $7,672 | $9,165 | -$10,136 | $28,174 | $461,620 | -$270,333 | $249,874 |
| Net income | -$1.0M | -$2.2M | -$5.8M | -$2.5M | -$78,292 | -$1.0M | -$1.3M | -$2.3M | -$168,147 | $508,448 |
| EPS (diluted) | $-0.12 | $-0.26 | $-0.75 | $-0.32 | $-0.01 | $-0.14 | $-0.19 | $-0.42 | $-0.03 | $0.12 |
| Operating cash flow | $2.5M | $357,903 | -$4.7M | -$1.5M | $954,170 | $1.3M | $233,511 | -$373,404 | $1.2M | -$222,314 |
| Free cash flow | $1.2M | -$107,822 | -$6.6M | -$5.5M | -$1.7M | -$2.8M | -$1.2M | -$2.4M | -$16.6M | -$3.8M |
| Cash & equivalents | $3.8M | $3.8M | $978,741 | $5.8M | $10.2M | $6.9M | $6.3M | $2.5M | $3.8M | $5.2M |
| Inventory | $9.3M | $7.1M | $7.8M | $6.0M | $3.1M | $2.1M | $2.5M | $2.3M | $2.0M | $2.1M |
| Total assets | $42.5M | $45.1M | $43.8M | $44.9M | $44.5M | $40.3M | $38.7M | $32.7M | $34.3M | $24.7M |
| Total liabilities | $15.5M | $17.6M | $18.8M | $14.5M | $11.9M | $12.1M | $9.7M | $11.0M | $10.7M | $5.0M |
| Shareholders' equity | $27.1M | $27.5M | $25.0M | $30.4M | $32.6M | $28.3M | $29.0M | $21.7M | $23.6M | $19.7M |
Growth · year-over-year · Revenue CAGR 13%
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue growth | +4.3% | +51.6% | -5.9% | -3.5% | +25.4% | +11.8% | +24.9% | +5.3% | — | — |
| Net income growth | — | — | — | — | — | — | — | — | -133.1% | -58.1% |
| EPS growth | — | — | — | — | — | — | — | — | -125.0% | -68.4% |
| Free cash flow growth | — | — | — | — | — | — | — | — | — | -2203.7% |
Each column is the change versus the prior fiscal year. Growth off a negative or zero base is shown as “—”. CAGR is the compound annual revenue growth across the years shown.
Computed from company filings · US · as of 2025-12-31. Facts plus Stocktoria's own computed scores — not investment advice.